MasonWrightFreemanMD

Endocrinology • Boston, MA

Diabetes, Lipid Metabolism

Professor of Medicine Chief, Lipid Metabolism Unit

Join to view full profile

Dr. Freeman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Freeman's full profile

Already have an account?

Office
Simches 7214
185 Cambridge St
Boston, MA 02114
Phone+1 617-724-7704

Fax+1 617-726-2879

Education & Training

Massachusetts General HospitalResidency, Internal Medicine, 1985 - 1985
Massachusetts General HospitalResidency, Internal Medicine, 1979 - 1984
University of California San Francisco School of MedicineClass of 1979

Certifications & Licensure

MA State Medical License 1981 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Clinical Trials

Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers Start of enrollment: 2009 Feb 01
Completed
Phase 1
Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes Start of enrollment: 2009 Jun 01
Completed
Phase 1
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus Start of enrollment: 2009 Dec 01
Completed
Phase 2
Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus Start of enrollment: 2011 Dec 01
Completed
Phase 2
Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Start of enrollment: 2016 Nov 01
Completed
Phase 1
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Start of enrollment: 2017 Sep 27
Completed
Phase 1
Absolute Bioavailability Study With Bexagliflozin Start of enrollment: 2018 Aug 01
Withdrawn
Phase 1
Ketamine for Major Depressive Disorder Start of enrollment: 2018 Dec 28
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin.
John J V McMurray, Scott D Solomon, J Paul Lock, Joseph M Massaro, Fang Zhu
Diabetes, Obesity & Metabolism. 2024-03-01
4 citations
Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial.
Yuan-Di Halvorsen, Annie L Conery, John Paul Lock, Wenjiong Zhou, Mason W Freeman
Diabetes, Obesity & Metabolism. 2023-10-01
12 citations
A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Yuan-Di Halvorsen, John Paul Lock, Juan P Frias, Francisco José Tinahones, Dominik Dahl
Diabetes, Obesity & Metabolism. 2023-01-01

Press Mentions

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific SessionsNovember 8th, 2022
CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming American Society of Nephrology Kidney Week 2022October 25th, 2022
CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension ResearchOctober 21st, 2022
Join now to see all

Grant Support

Analysis Of ABCA Transporter Function In Homologous Recombinant MiceNational Center For Research Resources2006–2009
Cell Biology Of ABCA1National Heart, Lung, And Blood Institute2002–2006
Genomic Analysis Of Stress And InflammationNational Heart, Lung, And Blood Institute2003–2004
Shared Microarray FacilityNational Heart, Lung, And Blood Institute2002–2004
Development And Characterization Of CD14 Deficient MiceNational Center For Research Resources2001–2004
Macrophage Scavenger Receptor In AtherosclerosisNational Heart, Lung, And Blood Institute2000–2003
Macrophaage Lipid Receptors In AtherosclerosisNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2002
Core--Molecular/Cell BiologyNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2002
Core--Molecular BiologyEunice Kennedy Shriver National Institute Of Child Health &Human Development1996–1999
Regulation Of Scavenger Receptors In AtherosclerosisNational Heart, Lung, And Blood Institute1990–1998